Cargando…
Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety Analysis
BACKGROUND: A recent trial unexpectedly reported that atrial fibrillation, when defined as serious, occurred more often in participants randomized to an annual infusion of the relatively new parenteral bisphosphonate, zoledronic acid, than among those given placebo, but had limited power. Two subseq...
Autores principales: | Grosso, Anthony, Douglas, Ian, Hingorani, Aroon, MacAllister, Raymond, Smeeth, Liam |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648983/ https://www.ncbi.nlm.nih.gov/pubmed/19266096 http://dx.doi.org/10.1371/journal.pone.0004720 |
Ejemplares similares
-
Could NICE guidance on the choice of blood pressure lowering drugs be simplified?
por: Sofat, Reecha, et al.
Publicado: (2012) -
Atrial fibrillation and the use of oral bisphosphonates
por: Pazianas, Michael, et al.
Publicado: (2011) -
Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study
por: Erichsen, R, et al.
Publicado: (2011) -
Pharmacological cardioversion for atrial fibrillation and flutter
por: Cordina, J, et al.
Publicado: (2006) -
Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
por: Naccarelli, Gerald V., et al.
Publicado: (2011)